Up-regulated A20 Promotes Proliferation, Regulates Cell Cycle Progression and Induces Chemotherapy Resistance of Acute Lymphoblastic Leukemia Cells.

Shuying Chen,Haiyan Xing,Shouyun Li,Jing Yu,Huan Li,Shuang Liu,Zheng Tian,Kejing Tang,Qing Rao,Min Wang,Jianxiang Wang
DOI: https://doi.org/10.1016/j.leukres.2015.06.004
IF: 3.715
2015-01-01
Leukemia Research
Abstract:A20, also known as tumor necrosis factor-α (TNFα)-induced protein 3 (TNFAIP3), has been identified as a key regulator of cell survival in many solid tumors. However, little is known about the protein expression level and function of A20 in acute lymphoblastic leukemia (ALL). In this study, we found that A20 is up-regulated in ALL patients and several cell lines. Knockdown of A20 in Jurkat, Nalm-6, and Reh cells resulted in reduced cell proliferation, which was associated with cell cycle arrest. Phospho-ERK (p-ERK) was also down-regulated, while p53 and p21 were up-regulated in A20 knockdown cells. In addition, A20 knockdown induced apoptosis in Jurkat and Reh cells and enhanced the sensitivity of these cell lines to chemotherapeutic drugs. These results indicate that A20 may stimulate cell proliferation by regulating cell cycle progression. A20 inhibited apoptosis in some types of ALL cells, thereby enhancing their resistance to chemotherapy. This effect was abolished through A20 silencing. These findings suggest that A20 may contribute to the pathogenesis of ALL and that it may be used as a new therapeutic target for ALL treatment.
What problem does this paper attempt to address?